|
Laboratory
of Pharmacology,
|
Curriculum Vitae: |
English - Ελληνικά |
|
|
Research Interests:
|
|
|
Publications: |
Tavridou A, Ragia G, and
Manolopoulos VG (2011) Emerging targets for the treatment of
dyslipidemia.
Curr Med Chem 18:909-922 Tavridou A, Efthimiadis A,
Efthimiadis I, and Manolopoulos VG (2010) Simvastatin-induced changes in
circulating oxidized low-density lipoprotein in different types of
dyslipidemia.
Heart Vessels 25:288-293 Ragia G, Nikolaidis E, Tavridou
A, Arvanitidis KI, Kanoni S, Dedoussis GV, Bougioukas G, and
Manolopoulos VG (2010) Endothelial nitric oxide synthase gene
polymorphisms - 786T > C and 894G > T in coronary artery bypass
graft surgery patients.
Hum Genomics 4:375-383 Ragia G, Nikolaidis E, Tavridou
A, Arvanitidis KI, Kanoni S, Dedoussis GV, Bougioukas G, and
Manolopoulos VG (2010) Renin-angiotensin-aldosterone system gene
polymorphisms in coronary artery bypass graft surgery patients.
J Renin
Angiotensin Aldosterone Syst 11:136-145 Manolopoulos VG, Ragia G, and Tavridou
A (2010)
Pharmacogenetics of coumarinic oral anticoagulants.
Pharmacogenomics 11:493-496 Iordanidou M, Tavridou A,
Petridis I, Kyroglou S, Kaklamanis L, Christakidis D, and Manolopoulos
VG (2010) Association of polymorphisms of the serotonergic system with
smoking initiation in Caucasians.
Drug Alcohol Depend 108:70-76 Iordanidou M, Tavridou A,
Petridis I, Arvanitidis KI, Christakidis D, Vargemezis V, and
Manolopoulos VG (2010) The serotonin transporter promoter polymorphism
(5-HTTLPR) is associated with type 2 diabetes.
Clin Chim Acta
411:167-171 Tavridou A, and
Manolopoulos VG (2009) Inhibitors of 5-lipoxygenase activating protein:
WO 2008/030369.
Expert Opin Ther Pat 19:1473-1476 Tavridou A, and
Manolopoulos VG (2009) EP2300 compounds: focusing on the
antiatherosclerotic properties of squalene synthase inhibitors.
Curr
Pharm Des 15:3167-3178 Tavridou A, Arvanitidis KI,
Tiptiri-Kourpeti A, Petridis I, Ragia G, Kyroglou S, Christakidis D, and
Manolopoulos VG (2009) Thr54 allele of fatty-acid binding protein 2 gene
is associated with obesity but not type 2 diabetes mellitus in a
Caucasian population.
Diabetes Res Clin Pract 84:132-137 Stakos DA, Tavridou A,
Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K,
Bourikas G, Manolopoulos VG, and Boudoulas H (2009) Oxidised low-density
lipoprotein and arterial function in beta-thalassemia major.
Eur J
Haematol 82:477-483 Ragia G, Petridis I, Tavridou
A, Christakidis D, and Manolopoulos VG (2009) Presence of CYP2C9*3
allele increases risk for hypoglycemia in Type 2 diabetic patients
treated with sulfonylureas.
Pharmacogenomics 10:1781-1787 Ragia G, Arvanitidis KI, Tavridou
A, and Manolopoulos VG (2009) Need for reassessment of reported
CYP2C19 allele frequencies in various populations in view of CYP2C19*17
discovery: the case of Greece.
Pharmacogenomics 10:43-49 Manolopoulos VG, and Tavridou
A (2009) Drugs targeting atherosclerosis: current and emerging
approaches.
Curr Pharm Des 15:3091-3093 Tavridou A, and
Manolopoulos VG (2008) Novel molecules targeting dyslipidemia and
atherosclerosis.
Curr Med Chem 15:792-802 Tavridou A, Kaklamanis L,
Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A,
and Manolopoulos VG (2008) Antiatherosclerotic properties of EP2302, a
novel squalene synthase inhibitor, in the cholesterol-fed rabbit.
J
Cardiovasc Pharmacol 51:573-580 Iordanidou M, Tavridou A,
Vasiliadis MV, Arvanitidis KI, Petridis J, Christakidis D, Vargemezis V,
Bougioukas G, and Manolopoulos VG (2008) The -759C/T polymorphism of the
5-HT2C receptor is associated with type 2 diabetes in male and female
Caucasians.
Pharmacogenet Genomics 18:153-159 Tavridou A, Megaritis G,
Kourounakis AP, Charalambous A, and Manolopoulos VG (2007) EP2306 and
EP2302, two novel squalene synthase inhibitors, stimulate endothelial
nitric oxide synthase expression in cultured endothelial cells.
Endothelium 14:239-243 Tavridou A, Kaklamanis L,
Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A,
and Manolopoulos VG (2007) EP2306
[2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a
novel squalene synthase inhibitor, reduces atherosclerosis in the
cholesterol-fed rabbit.
J Pharmacol Exp Ther
323:794-804 Arvanitidis K, Ragia G,
Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, and Manolopoulos
VG (2007) Genetic polymorphisms of drug-metabolizing enzymes CYP2D6,
CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Fundam Clin
Pharmacol 21:419-426 Tavridou A, Kaklamanis L,
Megaritis G, Kourounakis AP, Papalois A, Roukounas D, Rekka EA,
Kourounakis PN, Charalambous A, and Manolopoulos VG (2006)
Pharmacological characterization in vitro of EP2306 and EP2302, potent
inhibitors of squalene synthase and lipid biosynthesis.
Eur J Pharmacol
535:34-42 Tavridou A, Efthimiadis A,
Efthimiadis I, and Paschalidou H (2006) Antioxidant effects of
simvastatin in primary and secondary prevention of coronary heart
disease.
Eur J Clin Pharmacol 62:485-489 Vryonidou A, Papatheodorou A, Tavridou
A, Terzi T, Loi V, Vatalas IA, Batakis N, Phenekos C, and Dionyssiou-Asteriou
A (2005) Association of hyperandrogenemic and metabolic phenotype with
carotid intima-media thickness in young women with polycystic ovary
syndrome.
J Clin Endocrinol Metab 90:2740-2746 Tavridou A, and
Manolopoulos VG (2005) Atorvastatin and simvastatin decrease the uptake
of acetylated low-density lipoprotein by human monocytes.
Pharmacology
73:102-105 Tavridou A, and
Manolopoulos VG (2004) Antioxidant properties of two novel
2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo.
Eur J Pharmacol 505:213-221 Tavridou A, Unwin N,
Bhopal R, and Laker MF (2003) Predictors of lipoprotein(a) levels in a
European and South Asian population in the Newcastle Heart Project.
Eur
J Clin Invest 33:686-692 Tavridou A, and Agius L
(2003) Phosphorylase regulates the association of glycogen synthase with
a proteoglycogen substrate in hepatocytes.
FEBS Lett 551:87-91 Tavridou A, and Laker MF
(1999) Field inversion gel electrophoresis for apolipoprotein(a)
genotyping.
Anal Biochem 272:282-285 Bhopal R, Unwin N, White M,
Yallop J, Walker L, Alberti KG, Harland J, Patel S, Ahmad N, Turner C,
Watson B, Kaur D, Kulkarni A, Laker M, and Tavridou A (1999)
Heterogeneity of coronary heart disease risk factors in Indian,
Pakistani, Bangladeshi, and European origin populations: cross sectional
study.
BMJ 319:215-220 Tavridou A, Unwin NC,
Laker MF, White M, and Alberti KG (1997) Serum concentrations of
vitamins A and E in impaired glucose tolerance.
Clin Chim Acta
266:129-140 Tavridou A, Avranas A, and
Arzoglou P (1992) A mathematical approach to lipolysis based on the
interrelationship of physicochemical and biochemical data.
Biochem
Biophys Res Commun 186:746-752 Lessinger JM, Tavridou A,
Arzoglou P, and Ferard G (1992) Interest of using a purified, stable and
commutable preparation of human pancreatic lipase in indirect assays.
Analytical Letters 25:1453-1468 Arzoglou PL, Tavridou A,
Lessinger JM, Tzimas G, and Ferard G (1992) Spectrophotometric
determination of lipase activity in the presence of increased triolein
concentration.
Ann Biol Clin (Paris) 50:155-160 Arzoglou PL, Tavridou A, and Balaska C (1989) Rapid turbidimetric determination of lipase activity in biological fluids. Analytical Letters 22:1459-1470. |